ACRIVON THERAPEUTICS CORPORATE R&D AND KOL EVENT - ACRIVON THERAPEUTICS INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures disclosed, consistent with a pre-revenue biotech company.
• The acquisition of the INI assets (ACR525 and a PKC theta program) was made with no milestone or royalty obligations, and the asset is wholly owned.
• Management confirmed a need for future capital raise, planned for "sometime next year," with current runway guidance previously shared publicly.
• Cash flow implications involve funding the planned Phase 2 trials and continued development of the oncology portfolio (ACR2316, ACR7280).

Guidance and Future Outlook:

• ACR525 (JAK1 Inhibitor): Ready for Phase 2 initiation targeting Eosinophilic Esophagitis (EOE); aiming to establish a dose-response relationship with 50-60% target engagement.
• Trial Design: Anticipated Phase 2 duration of 12-20 weeks (potentially 16 weeks) with small sample sizes (15-25 patients per arm), possibly single-arm or placebo-controlled.
• Positioning: Targeting first-line therapy after PPIs or as second-line therapy, potentially replacing injectable biologics like dupilumab due to oral availability.
• PKC Theta Program: Remains in preclinical development; high selectivity noted; potential for combination therapy with ACR525.
• Long-term Goals: Execute the strategic narrative of utilizing the AI-driven AP3 platform to enter the Inflammatory and Immunological (INI) space; extending patent life beyond 2038.

Business Segments and Product Lines:

• ACR525 (formerly AQ280): Highly selective oral JAK1 inhibitor; shows desirable suppression of non-SMAD TGF-beta signaling (potentially antifibrotic); no activation of pro-apoptotic BAD signaling observed.
• Platform Strengths: Acroboron Predictive Precision Proteomics (AP3) is generative AI-driven, utilizing proprietary in-house phosphoproteomics data to map drug mechanisms and predict patient responders without relying on genetic alterations.
• Pipeline Updates:
  • ACR2316 (V1 PK-MET inhibitor): Continuing clinical benefit >65 weeks in heavily pre-treated lung cancer; confirmed complete response in squamous lung cancer; data to be presented at Triple Meeting in Barcelona.
  • ACR7280 (CDK11 inhibitor): Demonstrated complete regression in preclinical AML models.
  • ACR36A: Pre-specified interim analysis planned; no new data disclosed.
• Formulations: ACR525 available in capsule and tablet forms; specific "absorbable" formulation designed for high local concentration in the esophageal lining for EOE patients.

Market and Competitive Landscape:

• Target Disease (EOE): Annual incidence in the US estimated at 120,000; prevalence >500,000; incidence has grown ~500% over 30 years.
• Unmet Need: Current first-line treatments (PPIs, topical steroids) have suboptimal response rates (>50% non-responders), adherence issues, and risk of flaring. Biologics (dupilumab) are injectable and require frequent dosing.
• Competitive Advantage: ACR525 offers broader pathway inhibition than dupilumab (which only targets IL-4/IL-13) by covering the full JAK-STAT pathway and non-SMAD TGF-beta signaling. It is the first potential highly selective oral JAK1 inhibitor for EOE.
• Market Trends: Shift towards oral therapies and combination treatments; increasing focus on antifibrotic mechanisms in chronic inflammatory diseases.

Risks and Challenges:

• Regulatory Uncertainty: While high JAK1 selectivity may reduce risks, the final safety label and potential for black box warnings remain subject to regulatory review based on Phase 2/3 data.
• Safety Liabilities: JAK inhibitors face historical risks (e.g., rhabdomyolysis linked to pro-apoptotic pathways); management claims ACR525 avoids this but requires Phase 2 confirmation.
• Clinical Execution: Small sample size trials for EOE are feasible but rely on early biopsy endpoints; potential for recurrence upon discontinuation is a chronic disease characteristic.
• Capital Needs: Dependence on future fundraising to sustain operations and Phase 2 execution.

Management Commentary and Tone:

• Tone: Highly confident and optimistic; emphasized the strategic alignment of the acquisition with the company's AI-driven platform capabilities.
• Differentiation: Repeatedly stressed the "unbiased" global pathway mapping of AP3 as a key differentiator that identified desirable safety and efficacy features (e.g., TGF-beta suppression, lack of BAD activation) prior to clinical trials.
• Strategic Focus: Reinforced the transition from oncology into INI as a core execution of their original narrative.

Analyst Questions and Answers:

• Dosing Strategy: Phase 2 will likely evaluate two doses; target engagement of 50-60% is deemed sufficient for efficacy based on Phase 1 CXCL10 suppression data.
• Trial Design: Proposed 12-20 week trials with small cohorts (15-25 patients), utilizing esophageal biopsy biomarkers for rapid efficacy readouts.
• Positioning: Management and KOLs agree ACR525 could be positioned as first-line (post-PPI) or second-line therapy, offering a convenient oral alternative to injectable biologics.
• Formulation: Addressed dysphagia concerns by confirming capsule/tablet options and a specific liquid-absorbable formulation for esophageal coating.
• Combination Opportunities: Confirmed high potential for combining ACR525 with PKC theta inhibitors, IL-23 antagonists, and TNF antagonists, validated by AP3 profiling.
• Selectivity vs. Competitors: ACR525 shows superior JAK1/JAK2 selectivity (120x in cell-based assays) compared to Filgotinib (~20x), potentially offering a differentiated safety profile.

Other Key Points:

• Key Opinion Leaders (KOLs): Dr. Arjen Bredenoord and Dr. Evan Dellen provided expert context on EOE pathophysiology and the inadequacy of current treatments, validating the clinical rationale.
• Biomarker Capability: Leverage of single-cell phosphoproteomics and multiplex biomarker platforms for early endpoints in Phase 2 trials.
• Synergistic Mechanisms: Emphasis on the convergence of STAT and NF-kappa B pathways, supporting the rationale for JAK1 + PKC theta combination therapy.
• Acquisition Terms: Highlighted the "wholly owned" status of ACR525 with no future royalty obligations as a significant financial advantage.